ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Rongzhen Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5865-0589; OpenAlex author ID A5066607822, A5091690894. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 2

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

HERV-K TM Subunit Elicits CD8+ T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC. Last author DOI 10.1002/advs.202417432 ↗
In vivo vaccine generation with a topical small molecule cocktail to eradicates AML and PDAC Last author DOI 10.1101/2025.10.19.683274 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shusen Zheng · 1 shared paper, 2025 · strength 0.30
- Paper In vivo vaccine generation with a topical small molecule cocktail to eradicates AML and PDAC DOI 10.1101/2025.10.19.683274 ↗
Mengyuan Li · 1 shared paper, 2026 · strength 0.26
- Paper HERV-K TM Subunit Elicits CD8+ T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC. DOI 10.1002/advs.202417432 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.